You can buy or sell VRCA and other stocks, options, ETFs, and crypto commission-free!
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. Read More The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
West Chester, Pennsylvania
52 Week High
52 Week Low
Markets InsiderMar 2
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
– CAMP-1 and CAMP-2 trials of VP-102 for the treatment of molluscum contagiosum successfully met their primary endpoints – – Molluscum contagiosum is a highly contagious, significantly undertreated viral skin disease that affects approximately six million people in the U.S., many of them children, with no-FDA approved treatment – WEST CHESTER, Pa., March 02, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commer...
-$0.27 per share
-$0.30 per share